HRP20191306T1 - Postupak proizvodnje lijekova - Google Patents

Postupak proizvodnje lijekova Download PDF

Info

Publication number
HRP20191306T1
HRP20191306T1 HRP20191306TT HRP20191306T HRP20191306T1 HR P20191306 T1 HRP20191306 T1 HR P20191306T1 HR P20191306T T HRP20191306T T HR P20191306TT HR P20191306 T HRP20191306 T HR P20191306T HR P20191306 T1 HRP20191306 T1 HR P20191306T1
Authority
HR
Croatia
Prior art keywords
solvent
give
ketoreductase
agent
strong base
Prior art date
Application number
HRP20191306TT
Other languages
English (en)
Croatian (hr)
Inventor
Jinguang LIN
Alexandra CHESTAKOVA
Wei Gu
Hans Iding
Jing Li
Xin Linghu
Patrik Meier
Chunbo SHA
Jeffrey Stults
Youchu Wang
Haiming Zhang
Jianqian ZHANG
Tao Zhang
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of HRP20191306T1 publication Critical patent/HRP20191306T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
HRP20191306TT 2014-04-09 2015-04-08 Postupak proizvodnje lijekova HRP20191306T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014075011 2014-04-09
EP15776904.3A EP3129025B1 (en) 2014-04-09 2015-04-08 Process for the manufacturing of medicaments
PCT/CN2015/076083 WO2015154674A1 (en) 2014-04-09 2015-04-08 Process for the manufacturing of medicaments

Publications (1)

Publication Number Publication Date
HRP20191306T1 true HRP20191306T1 (hr) 2019-10-18

Family

ID=54287327

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191306TT HRP20191306T1 (hr) 2014-04-09 2015-04-08 Postupak proizvodnje lijekova

Country Status (22)

Country Link
US (4) US20170022183A1 (enExample)
EP (2) EP3494971B1 (enExample)
JP (3) JP6723926B2 (enExample)
KR (3) KR20200038553A (enExample)
CN (3) CN112645927A (enExample)
AR (1) AR099989A1 (enExample)
AU (2) AU2015245743B2 (enExample)
BR (2) BR122020014933B8 (enExample)
CA (2) CA2945098C (enExample)
ES (1) ES2733495T3 (enExample)
HR (1) HRP20191306T1 (enExample)
IL (2) IL248205B (enExample)
MX (2) MX375638B (enExample)
MY (3) MY188526A (enExample)
NZ (1) NZ725450A (enExample)
PL (1) PL3129025T3 (enExample)
RU (1) RU2684102C2 (enExample)
SG (1) SG11201608421XA (enExample)
SI (1) SI3129025T1 (enExample)
TW (2) TWI678366B (enExample)
WO (1) WO2015154674A1 (enExample)
ZA (1) ZA201607066B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201800282T1 (it) * 2012-03-01 2018-07-17 Genentech Inc Inibitori delle serina/treonina chinasi
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
UA120506C2 (uk) 2013-12-06 2019-12-26 Дженентек, Інк. Інгібітори серин/треонінкіназ
EP3494971B1 (en) 2014-04-09 2024-07-24 Genentech, Inc. Salts of erk inhibitors
CR20180316A (es) 2015-11-09 2018-10-05 Astrazeneca Ab Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
KR20180134347A (ko) 2016-04-15 2018-12-18 제넨테크, 인크. 암의 진단 및 치료 방법
JP7530829B2 (ja) 2017-09-08 2024-08-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの診断及び治療方法
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
EP3546447A1 (en) * 2018-03-29 2019-10-02 Heidelberg Pharma GmbH Synthesis of (2s,3r,4r)-4,5-dihydroxyisoleucine and derivatives
WO2021110893A1 (en) * 2019-12-05 2021-06-10 Astrazeneca Ab Process and intermediates for the production of formula (i)
CN115710158A (zh) * 2021-08-23 2023-02-24 凯特立斯（深圳）科技有限公司 一种不对称催化制备替格瑞洛中间体的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
US6869966B2 (en) * 2002-09-30 2005-03-22 Banyu Pharmaceutical Co., Ltd. N-substituted-2-oxodihydropyridine derivatives
EP2001849B1 (en) * 2006-03-29 2014-11-26 F. Hoffmann-La Roche AG Pyridine and pyrimidine derivatives as mglur2 antagonists
JP2011503006A (ja) * 2007-11-06 2011-01-27 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺菌性複素環アミン
SMT201800282T1 (it) * 2012-03-01 2018-07-17 Genentech Inc Inibitori delle serina/treonina chinasi
US9867667B2 (en) * 2014-02-27 2018-01-16 Canon Usa Inc. Placement apparatus
EP3494971B1 (en) 2014-04-09 2024-07-24 Genentech, Inc. Salts of erk inhibitors

Also Published As

Publication number Publication date
JP2020114817A (ja) 2020-07-30
EP3129025A1 (en) 2017-02-15
EP3494971C0 (en) 2024-07-24
JP2021167321A (ja) 2021-10-21
CN106659721B (zh) 2021-01-01
TWI762806B (zh) 2022-05-01
ZA201607066B (en) 2018-05-30
CN106659721A (zh) 2017-05-10
RU2684102C2 (ru) 2019-04-04
EP3494971B1 (en) 2024-07-24
AU2015245743A1 (en) 2016-10-27
CN111777594B (zh) 2023-06-27
BR122020014933B1 (pt) 2022-11-29
CA3167641A1 (en) 2015-10-15
TWI678366B (zh) 2019-12-01
MX2020010384A (es) 2022-05-19
JP6974524B2 (ja) 2021-12-01
MX2016013162A (es) 2017-04-27
BR112016023391A2 (enExample) 2017-08-15
CN112645927A (zh) 2021-04-13
US20180134685A1 (en) 2018-05-17
ES2733495T3 (es) 2019-11-29
NZ725450A (en) 2022-08-26
BR112016023391B1 (pt) 2022-08-09
JP6723926B2 (ja) 2020-07-15
RU2016139286A3 (enExample) 2018-10-26
US20200190061A1 (en) 2020-06-18
MX392460B (es) 2025-03-24
US10611753B2 (en) 2020-04-07
IL268690A (en) 2019-10-31
MY188526A (en) 2021-12-18
AU2020220208B2 (en) 2022-03-17
EP3129025A4 (en) 2018-01-17
JP2017510620A (ja) 2017-04-13
RU2016139286A (ru) 2018-05-15
KR20230006043A (ko) 2023-01-10
US11098028B2 (en) 2021-08-24
KR102490955B1 (ko) 2023-01-19
BR122020014933B8 (pt) 2022-12-13
BR112016023391A8 (pt) 2018-04-17
MY196320A (en) 2023-03-24
US11066389B2 (en) 2021-07-20
EP3494971A1 (en) 2019-06-12
US20170022183A1 (en) 2017-01-26
CA2945098A1 (en) 2015-10-15
IL248205B (en) 2019-09-26
AU2015245743B2 (en) 2020-09-24
EP3129025B1 (en) 2019-05-15
CA2945098C (en) 2022-10-04
WO2015154674A1 (en) 2015-10-15
MX375638B (es) 2025-03-06
AR099989A1 (es) 2016-08-31
PL3129025T3 (pl) 2019-11-29
TW201945358A (zh) 2019-12-01
KR20200038553A (ko) 2020-04-13
SG11201608421XA (en) 2016-11-29
CN111777594A (zh) 2020-10-16
TW201620897A (zh) 2016-06-16
IL248205A0 (en) 2016-11-30
US20190367484A1 (en) 2019-12-05
AU2020220208A1 (en) 2020-09-10
KR20160133566A (ko) 2016-11-22
MY198371A (en) 2023-08-28
SI3129025T1 (sl) 2019-08-30

Similar Documents

Publication Publication Date Title
HRP20191306T1 (hr) Postupak proizvodnje lijekova
IL290720B1 (en) Molecules for use in pest control, and intermediates, preparations, and processes related thereto
JP6963557B2 (ja) ４−（（６−（２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−２−ヒドロキシ−３−（１ｈ−１，２，４−トリアゾール−１−イル）プロピル）ピリジン−３−イル）オキシ）ベンゾニトリル及び調製方法
TWI636049B (zh) 製備４－（（６－（２－（２，４－二氟苯基）－１，１－二氟－２－羥基－３－（１ｈ－１，２，４－三唑－１－基）丙基）吡啶－３－基）氧基）苄腈之方法
KR20160134672A (ko) 2-(2,4-디플루오로페닐)-1,1-디플루오로-1-(5-치환된-피리딘-2-일)-3-(1h-테트라졸-1-일)프로판-2-올 및 이의 제조방법
Bannwarth et al. Flexible synthesis of pyrimidines with chiral monofluorinated and difluoromethyl side chains
WO2016082605A1 (zh) 帕博西尼的制备方法
US20180327359A1 (en) 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-oxoethyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation
CN103508899A (zh) 一种制备替格瑞洛关键中间体及其消旋体的方法和实施该方法的专用中间体
RU2012156217A (ru) СПОСОБ ПОЛУЧЕНИЯ 5-ЗАМЕЩЕННЫХ-8-АЛКОКСИ[1,2,4]ТРИАЗОЛО[1,5-c]ПИРИМИДИН-2-АМИНОВ
US20160289718A1 (en) Process for the preparation of chiral 2-aryl morpholines
EP1104762A1 (en) Substituted imidazo 1,2a]azines as selective inhibotors of cox-2
JP5077969B2 (ja) ２−置換５−（１−アルキルチオ）アルキルピリジンの調製方法
WO2017091453A1 (en) Novel processes for making substituted quinazoline compounds using hydrogen bonding catalysts
DK153401B (da) 4-halogen-6-hydroxy-2h-pyran-3(6h)-on-forbindelser til anvendelse som mellemprodukter ved fremstilling af gamma-pyroner og fremgangsmaade til fremstilling af mellemprodukt-forbindelserne
JP2002003486A (ja) ピラノン
CN110483406B (zh) 一种合成含n-二氟甲基类化合物的方法
US9856212B1 (en) Biphenyl compounds and applications thereof
US4429167A (en) 3-Alkoxy-4-substituted-phenoxy-2,3-unsaturated acids, esters and derivatives
US20170190684A1 (en) Preparation method for chiral intermediate for use in statins
TWI450904B (zh) 製備去氧呋喃核糖之方法
US20160060253A1 (en) Methods of synthesizing a difluorolactam analog
Pang et al. Regioselective Carbon-Carbon Bond Formation in the Reaction of 2-Hydroxy-2-(trifluoromethyl)-2H-chromenes with Indoles Promoted by Lewis Acid
CN112645871A (zh) N-cf2h-1,2-二氢吡啶-2-酮化合物的合成方法
Ohta et al. Scandium-catalyzed propargylation of 1, 3-diketones with propargyl alcohols bearing sulfur or selenium functional groups: Useful transformation to furans and pyrans